Consensus or Controversy? Documenting and Discussing Investigators’ Approaches to the Management of Colorectal Cancer

A CME Symposium Held Adjunct with the 2026 ASCO® Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400

Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 8:00 PM — Educational Meeting

Meeting Room
Continental Room C (Lobby Level)

No registration fee is charged for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

Faculty

Andrea Cercek

Faculty

Andrea Cercek

MD

Memorial Sloan Kettering Cancer Center, New York, New York

Section Head, Colorectal Cancer, Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers, Attending, Gastrointestinal Oncology Service, Department of Medicine

Arvind Dasari

Faculty

Arvind Dasari

MD, MS

The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Department of Gastrointestinal Medical Oncology

Tanios Bekaii-Saab

Moderator

Tanios Bekaii-Saab

MD

Mayo Clinic Comprehensive Cancer Center (All Sites)

David F and Margaret T Grohne Professor of Novel Therapeutics for Cancer Research I, Chair and Consultant, Division of Hematology and Medical Oncology, Co-Leader, Advanced Clinical and Translational Science Program

Mayo Clinic in Arizona, Phoenix, Arizona

Professor, Mayo Clinic College of Medicine and Science

This activity is supported by educational grants from Exelixis Inc, GSK, and Natera Inc.

Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 8:00 PM — Educational Meeting

MODULE 1: Current and Future Role of Immune Checkpoint Inhibition in the Management of Microsatellite Instability-High (MSI-H)/Mismatch Repair-Deficient (dMMR) Localized and Locally Advanced Colorectal Cancer (CRC)

  • Current role of neoadjuvant and adjuvant systemic treatment in localized/locally advanced rectal and colon tumors; historical outcomes achieved with chemotherapy and chemoradiation therapy for patients with MSI-H/dMMR disease
  • Updated results with dostarlimab as an alternative to surgery for MSI-H/dMMR locally advanced rectal cancer; implications for organ preservation
  • FDA breakthrough therapy designation for dostarlimab for patients with locally advanced MSI-H/dMMR rectal cancer; ongoing evaluation in the registrational Phase II AZUR-1 trial
  • Early-phase data with neoadjuvant anti-PD-1/PD-L1 antibodies alone or in combination with other immunotherapies for patients with nonmetastatic MSI-H/dMMR colon cancer; ongoing Phase III AZUR-2 study of perioperative dostarlimab in this population
  • Design, eligibility criteria and key efficacy and safety findings from the Phase III Alliance A021502/ATOMIC trial assessing atezolizumab in combination with mFOLFOX6 and continued as monotherapy in the adjuvant setting for patients with Stage III CRC and dMMR tumors
  • Patient selection for and potential role of adjuvant atezolizumab for patients with Stage III CRC

MODULE 2: Clinical Relevance and Practical Use of Molecular Residual Disease (MRD) Analysis in CRC

  • Biological rationale for circulating tumor DNA (ctDNA)-based MRD monitoring in CRC; benefits of ctDNA monitoring over traditional means of follow-up
  • Published datasets (eg, the CIRCULATE-Japan and BESPOKE CRC trials) evaluating the use of ctDNA testing to identify patients at increased risk of recurrence
  • Recent findings from various studies (eg, the DYNAMIC, CALGB/SWOG-80702, ALTAIR and ALASCCA trials) attempting to validate the use of ctDNA testing in predicting benefit from adjuvant treatment regimens
  • Ongoing Phase III trials examining the clinical utility of ctDNA-based MRD testing for guiding treatment decision-making in localized CRC
  • Available evidence supporting the use of ctDNA as a tool for monitoring for recurrence after curative-intent therapy; recommended timing and frequency of ctDNA testing in the surveillance setting
  • Current and potential future role of ctDNA testing in localized, locally advanced and metastatic CRC

MODULE 3: Recent Advances in Metastatic CRC (mCRC) — Optimizing Immunotherapy and Other Approaches

  • Rationale for the evaluation of dual immune checkpoint inhibition for newly diagnosed mCRC
  • Design, eligibility criteria and key endpoints of the Phase III CheckMate 8HW trial assessing nivolumab/ipilimumab versus chemotherapy with or without bevacizumab or cetuximab for previously untreated MSI-H/dMMR mCRC
  • Key efficacy and safety findings from the CheckMate 8HW trial assessing nivolumab/ipilimumab versus chemotherapy with or without bevacizumab or cetuximab for previously untreated MSI-H/dMMR mCRC; FDA approval and current role of nivolumab/ipilimumab in first-line therapy
  • Biological rationale for dual targeting of EGFR and MET with amivantamab for patients with mCRC
  • Available efficacy and safety findings from the Phase Ib/II OrigAMI-1 trial evaluating amivantamab as monotherapy and in combination with chemotherapy for patients with mCRC
  • Design, eligibility criteria and primary and secondary endpoints of the Phase III OrigAMI-2 and OrigAMI-3 trials evaluating subcutaneous amivantamab with FOLFOX and FOLFIRI; potential clinical role of amivantamab in therapy for patients with mCRC
  • Available data with immune checkpoint inhibitors alone and in combination with other agents for patients with microsatellite-stable (MSS)/mismatch repair-proficient (pMMR) mCRC
  • Mechanistic similarities and differences between zanzalintinib and other multikinase inhibitors for CRC; rationale for combining zanzalintinib with an anti-PD-1/PD-L1 antibody in therapy for mCRC
  • Recently presented efficacy and safety findings from the Phase III STELLAR-303 trial evaluating zanzalintinib with atezolizumab for pretreated MSS/pMMR mCRC; implications for therapeutic sequencing
  • Future development plans for zanzalintinib/atezolizumab in the management of CRC and implications for therapeutic sequencing
  • Available data with and optimal use of targeted therapy for patients with mCRC and a BRAF, HER2 or KRAS G12C mutation

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of colorectal cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Understand validated biomarkers of response (eg, RAS mutations, microsatellite instability (MSI)/mismatch repair (MMR) deficiency, HER2 overexpression, BRAF V600E mutations, KRAS G12C mutations) found in patients with CRC, and consider the implications for molecular testing and clinical care.
  • Evaluate the biological rationale for the use of immune checkpoint inhibitors in the management of MSI-high (MSI-H)/mismatch repair-deficient (dMMR) localized and advanced CRC, and counsel patients regarding evidence-based and guideline-endorsed treatment recommendations.
  • Optimize the current and future use of neoadjuvant and adjuvant therapy for patients with localized and locally advanced CRC, considering the influence of various clinical and biological factors such as MSI-H/dMMR status.
  • Recognize the clinical relevance of circulating tumor DNA (ctDNA) as a prognostic and predictive biomarker in CRC, and comprehend the rationale for its use in detecting molecular residual disease.
  • Appreciate published datasets documenting the clinical utility of ctDNA testing in risk stratification, surveillance and treatment decision-making for patients with CRC, and consider the current and future role of this strategy in personalizing therapeutic recommendations.
  • Formulate a plan to guide the selection and sequencing of therapies for patients diagnosed with metastatic CRC (mCRC) accounting for tumor sidedness, biomarker profile, prior systemic therapy, symptomatology and personal goals of treatment.
  • Appreciate published research documenting the efficacy of targeted therapeutic approaches for patients with mCRC and various actionable genomic alterations in order to personalize treatment recommendations.
  • Recall ongoing trials evaluating novel agents and strategies for patients with mCRC, and use this information to refer candidates for study participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Cercek — Advisory Boards: 3T Biosciences, AbbVie Inc, Agents, Amgen Inc, Daiichi Sankyo Inc, GSK, Janssen Biotech Inc, Merck, Pfizer Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Summit Therapeutics, UroGen Pharma; Contracted Research: GSK, Pfizer Inc. Dr Dasari — Advisory Committees: Agenus Inc, Bristol Myers Squibb, Exelixis Inc, Illumina, Lantheus, Personalis, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol Myers Squibb, Crinetics Pharmaceuticals, Eisai Inc, Enterome, Guardant Health, Hutchison MediPharma, Natera Inc, NeoGenomics, Personalis, RayzeBio, Taiho Oncology Inc, Xencor.

MODERATOR
Dr Bekaii-Saab — Consulting Agreements (to Institution): Arcus Biosciences, Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Merck KGaA, Merus, Pfizer Inc, Revolution Medicines, Seagen Inc, Servier Pharmaceuticals LLC; Consulting Agreements (to Self): AbbVie Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BeOne, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, Exact Sciences Corporation, Exelixis Inc, Foundation Medicine, GSK, Illumina, Janssen Biotech Inc, Kanaph Therapeutics, Lisata Therapeutics, Natera Inc, Sanofi, Sobi, Stemline Therapeutics Inc, Takeda Pharmaceuticals USA Inc, Treos Bio, Xilio Therapeutics, Zai Lab; Data and Safety Monitoring Boards/Committees: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, FibroGen Inc, Merck, Suzhou Kintor; Inventions/Patents: WO/2018/183488 licensed to Imugene, WO/2019/055687 licensed to Recursion; Research Funding (to Institution): Agios Pharmaceuticals Inc, AltruBio, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merus, Mirati Therapeutics Inc, Novartis, Pfizer Inc, pharmaand GmbH, Seagen Inc, Sumitomo Pharma America; Scientific Advisory Boards: Artiva Biotherapeutics Inc, Immuneering Corporation, Imugene, Panbela Therapeutics Inc, Replimune, Xilis; Nonrelevant Financial Relationships: MJH Life Sciences, Pancreatic Cancer Action Network, The Valley Hospital.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Exelixis Inc, GSK, and Natera Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room C (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

You have successfully registered

See you on Friday, May 29

Format:

Chicago, IL
Date & Time:

Friday, May 29 6:30 PM — 8:00 PM CT

Clinical Investigators Review Actual Cases of Patients with HER2-Positive Gastrointestinal Cancers

Accreditation types: 1.25 ABIM MOC, ABS MOC, CME

Expires: November 2026

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Tanios Bekaii-Saab

Faculty

Tanios Bekaii-Saab

MD

Mayo Clinic Comprehensive Cancer Center (All Sites)

David F and Margaret T Grohne Professor of Novel Therapeutics for Cancer Research I, Chair and Consultant, Division of Hematology and Medical Oncology, Co-Leader, Advanced Clinical and Translational Science Program

Mayo Clinic in Arizona, Phoenix, Arizona

Professor, Mayo Clinic College of Medicine and Science

Kristen K Ciombor

Faculty

Kristen K Ciombor

MD, MSCI

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

Associate Professor of Medicine, Division of Hematology/Oncology

TARGET AUDIENCE
This program is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

LEARNING OBJECTIVES

  • Appreciate the prevalence and clinical relevance of HER2 amplification/overexpression in various gastrointestinal (GI) cancers, and consider the implications for biomarker assessment and clinical management.
  • Evaluate available clinical trial findings with HER2-directed therapies for HER2-positive biliary tract cancers, and optimally incorporate available agents into the care of appropriately selected patients.
  • Review published research findings with established and investigational HER2-targeted therapies for patients with HER2-positive gastroesophageal cancers, and assess the current and future role of various agents and regimens.
  • Recall available data with HER2-targeted agents and strategies for previously treated HER2-overexpressing colorectal cancer, and optimally identify patients who may be appropriate for these approaches.
  • Appraise the side effects associated with available and investigational HER2-directed therapies with established efficacy in GI cancers, and use this information to develop supportive care plans for patients.
  • Recall the design of ongoing clinical trials evaluating novel HER2-directed agents and strategies for advanced HER2-positive GI cancers, and appropriately counsel patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology..

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/PP2025/HER2PosGI/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Tanios Bekaii-Saab, MD
David F and Margaret T Grohne Professor of Novel Therapeutics
for Cancer Research I
Chair and Consultant, Division of Hematology and Medical Oncology
Co-Leader, Advanced Clinical and Translational Science Program
Mayo Clinic Comprehensive Cancer Center (All Sites)
Professor, Mayo Clinic College of Medicine and Science
Mayo Clinic in Arizona
Phoenix, Arizona

Consulting Agreements (to Institution): Arcus Biosciences, Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Merck KGaA, Merus, Pfizer Inc, Revolution Medicines, Seagen Inc, Servier Pharmaceuticals LLC; Consulting Agreements (to Self): AbbVie Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BeOne, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, Exact Sciences Corporation, Exelixis Inc, Foundation Medicine, GSK, Illumina, Janssen Biotech Inc, Kanaph Therapeutics, Lisata Therapeutics, Natera Inc, Sanofi, Sobi, Stemline Therapeutics Inc, Takeda Pharmaceuticals USA Inc, Treos Bio, Xilio Therapeutics, Zai Lab; Data and Safety Monitoring Boards/Committees: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, FibroGen Inc, Merck, Suzhou Kintor; Inventions/Patents: WO/2018/183488 licensed to Imugene, WO/2019/055687 licensed to Recursion; Research Funding (to Institution): Agios Pharmaceuticals Inc, AltruBio, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merus, Mirati Therapeutics Inc, Novartis, Pfizer Inc, pharmaand GmbH, Seagen Inc, Sumitomo Pharma America; Scientific Advisory Boards: Artiva Biotherapeutics Inc, Immuneering Corporation, Imugene, Panbela Therapeutics Inc, Replimune, Xilis; Nonrelevant Financial Relationships: MJH Life Sciences, Pancreatic Cancer Action Network, The Valley Hospital.

Kristen K Ciombor, MD, MSCI
Associate Professor of Medicine
Division of Hematology/Oncology
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Advisory Committees and Consulting Agreements: Agenus Inc, ALX Oncology, Bayer HealthCare Pharmaceuticals, BeOne, Exact Sciences Corporation, Exelixis Inc, Incyte Corporation, Merck, Pfizer Inc, Summit Therapeutics, Taiho Oncology Inc, Tempus; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Biomea Fusion Inc, Bristol Myers Squibb, Calithera Biosciences, Genentech, a member of the Roche Group, Incyte Corporation, Merck, NuCana, Pfizer Inc, Seagen Inc, Syndax Pharmaceuticals; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company. 

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

These activities are supported by an educational grant from Jazz Pharmaceuticals Inc.

Release date: November 2025
Expiration date: November 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Ayasun R et al. The role of HER2 status in the biliary tract cancers. Cancers (Basel) 2023;15(9):2628. Abstract

Bekaii-Saab TS et al. MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer. ASCO 2023;Abstract TPS3631.

Catenacci DVT et al. MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma — Trial in progress. Gastrointestinal Cancers Symposium 2022;Abstract TPS371.

Elimova E et al. Long-term outcomes and overall survival (OS) for zanidatamab + chemotherapy in HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA): 4-year follow-up of a phase 2 trial. ASCO 2025;Abstract 4013.

Galdy S et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: A potential therapeutic target? Cancer Metastasis Rev 2017;36(1):141-57. Abstract

Geyer CE et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05. ESMO 2025;Abstract LBA1.

Harbeck N et al. DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC). ESMO 2025;Abstract 291O.

Harding J et al. HERIZON-BTC-302: A phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC). Gastrointestinal Cancers Symposium 2025;Abstract TPS648.

Jacobi O et al. ERBB2 pathway in biliary tract carcinoma: Clinical implications of a targetable pathway. Oncol Res Treat 2021;44(1-2):20-7. Abstract

Javle M et al. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer 2016;15;122(24):3838-47. Abstract

Kanwal W et al. Exploring zanidatamab’s efficacy across HER2-positive malignancies: A narrative review. BMC Cancer 2025;25(1):382. Abstract

Kehmann L et al. Evolving therapeutic landscape of advanced biliary tract cancer: From chemotherapy to molecular targets. ESMO Open 2024;9(10):103706. Abstract

Lee K-W et al. A 2-year follow-up of zanidatamab (Zani) + mFOLFOX6 ± bevacizumab (Bev) in first-line (1L) treatment of patients with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic colorectal cancer (mCRC). ESMO 2025;Abstract 746P.

Mercade TM et al. HERIZON-BTC-302: A phase III study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC). ESMO 2024;Abstract 62TiP.

Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47-58. Abstract

Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. ASCO 2023;Abstract LBA3000.

Pant S et al. Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study. ASCO 2024;Abstract 4091.

Raghav KPS et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. ASCO 2023;Abstract 3501.

Rha SY et al. Zanidatamab (Zani) + chemotherapy (CT) in first-line (1L) human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic colorectal cancer (mCRC). ESMO 2024;Abstract 516MO.

Shitara K et al. Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study. ASCO 2025;Abstract LBA4002.

Søreide K et al; joint ESSO-EAHPBA-UEMS core curriculum working group. Biliary tract cancer. Eur J Surg Oncol 2025;51(6):108489. Abstract

Strickler JH et al. Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER). ASCO 2024;Abstract 3509.

Subbiah V et al. DiscovHER PAN-206: Phase II tumour-agnostic study of zanidatamab in patients with previously treated human epidermal growth factor receptor 2 (HER2)-overexpressing solid tumours. ESMO 2025;Abstract 1028eTiP.

Tabernero J et al. HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol 2022;18(29):3255-66. Abstract

Uzunparmak B et al. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol 2023;34(11):1035-46. Abstract